There is on-going development of generic EU CTD Dossier of Irbesartan, tablets, 75-150-300 mg.
Dossier should be available in October 2006.
Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.
Irbesartan is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Nephropathy in Type 2 Diabetic Patients
Irbesartan is indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. In this population, Irbesartan reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation)
More details at http://www.rxlist.com/cgi/generic/irbesart.htm
Name | Description |
---|---|
Pharma licensing | Out-licensing (offer) |